贝伐单抗治疗mCRC研究进展
摘要
总结贝伐单抗治疗转移性结直肠癌的研究进展。概述基本的治疗方案的同时,综合较新的临床研究进行相应的分析。结果表明:贝伐单抗联合不同化疗方案治疗转移性结直肠癌疗效显著,且不会加重化疗所产生的副作用。结论表明:转移性结直肠癌患者适合采用贝伐单抗联合使用化疗方案的治疗方式。
出处
《现代商贸工业》
2013年第7期86-87,共2页
Modern Business Trade Industry
参考文献8
-
1Howell JD, McArdle CS, Kerr DJ etc. A phase II study of regional 2-weekly 5-fluorouraeil infusion with intravenous folinic acid in the treatment of colorectal liver metastases[J]. Br J Cancer. 1997 ; 76(10) :1390 - 1393.
-
2Joulia JM, Pinguet F, Ychou M etc. Pharmacokinetics of 5-flu- orouracil (5-FUra)in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LVSFU2)[J]. Antieancer Res. 1997 Jul-Aug; 17 (4A) :2727-30.
-
3Meta-analysis Group In Cancer. Efficacy of intravenous continu- ous infusion of fluorouracil compared with bolus administration in advaneedeolorectal cancer[J]. ClinOncol, 1998,16 (1) : 301-308.
-
4Charles S. Fuchs,John Marshall,Edith Mitchell etc. Randomized, Controlled Trial of Irinotecan Plus Infusional,Bolus, or Oral Flu- oropyrimidines in First-Linen Treatment of Metastatic Colorectal Cancer : Results From the BICC-C Study[J]. Journal of clinical on- coiogy,2007,25(30) :4779-86.
-
5张红梅,徐伶伶,安广宇.贝伐单抗联合FOLFIRI方案一线治疗转移性结直肠癌的临床评价[J].肿瘤防治研究,2012,39(8):1001-1004. 被引量：9
-
6Pectasides D,Papaxoinis G, Kalogeras KT etc XELIRI-bevacizum- ab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer.a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis[-J]. BMC Cancer. 2012 Jun 29;12:271.
-
7Kato S' Andoh H,Gamoh M Safety verification trials of mFOLFI- RI and sequential IRIS if- bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients[J]. Oncology. 2012 ;83(2) : 101-7.
-
8Hong YS, Lee J, Kim KP Muhicenter phase II study of second- line bevacizumab plus doublet combination chemotherapy in pa- tients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy[-J]. Invest New Drugs. 2012 ; 30(18) 1983-2012.
二级参考文献10
-
1Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer pa tients[J]. Eur J Cancer,2000,36(6) : 748-53.
-
2Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic coloreetal cancer:a multicentre randomlsed trial[J]. Lancet,2000,355(9209) :I041-7.
-
3Kabbinavar F, Irl C,Zurlo A, et al. Bevaeizumab improves the overall and progression-free survival of patients with metastatic colorec tal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk[J]. Ontology,2008,75(3-4) :215 23.
-
4Kabbinavar FF, Hurwitz HI, Yi J, et al. Addition of bevacizumab to fluorouracil based first-line treatment of metastatic color ectal cancer; pooled analysis of cohorts of older patients from two randomized clinical trials [J]. J Clin Oncol, 2009,27 (2): 199 205.
-
5Chowdhury MW, Scaramuzzi R J, Wheeler-Jones CP, et al. The expression of angiogenic growth factors and their receptors in ovarian follicles throughout the estrous cycle in the ewe[J]. Theriogenology,2010,73 (7) :856-72.
-
6Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer[J]. Clin Colorectal Caneer,2004,4(Suppl 2) :S62-8.
-
7Tyagi P ,Grothey A. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first line treatment of metastatic colorectal cancer: the NO16966 trial[J]. Clin Colorectal Cancer,2006,6(4) :261-4.
-
8Okines A,Puerto OD,Cunningham D,et al. Surgery with cura tive-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial[J]. Br J Cancer,2009, 101(7) : 1033-8.
-
9Sobrero A, Ackland S,Ciarke S, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil,leucovor- in and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer[J]. Oncology, 20(19,77(2) : 113-9.
-
10董志伟,乔友林,李连弟,王国清,张思维,孟祥柱,李纪宾.中国癌症高发现场报告[J].中国肿瘤,2009,18(1):4-9. 被引量：50
共引文献8
-
1张志安.健脾扶正方联合化疗治疗晚期结直肠癌临床观察[J].辽宁中医杂志,2013,40(9):1863-1864. 被引量：6
-
2李康.康艾注射液联合化疗治疗晚期结肠癌临床疗效研究[J].辽宁中医药大学学报,2014,16(11):19-21. 被引量：10
-
3徐阳,曹京旭.FOLFIRI化疗方案联合贝伐单抗治疗转移性结直肠癌的临床观察[J].临床医药文献电子杂志,2014,1(17):2449-2449. 被引量：3
-
4李刚,叶平江,应晓江,刘江.艾迪联合FOLFIRI方案治疗晚期结直肠癌患者的疗效研究[J].中华全科医学,2015,13(9):1414-1416. 被引量：11
-
5聂敏,李春雨.康艾注射液联合化疗治疗晚期结直肠癌临床观察及护理干预[J].山西医药杂志,2016,45(22):2716-2718. 被引量：3
-
6郭莉.评价分析康艾注射液联合化疗治疗晚期结肠癌的临床价值[J].中国医药指南,2016,14(31):133-134. 被引量：2
-
7李伟,李威威,宋锐,张海萍.贝伐珠单抗或抗EGFR单抗联合FOLFOX方案治疗晚期转移性结直肠癌的临床研究[J].河北医药,2017,39(8):1237-1239. 被引量：15
-
8许晓东.FOLFIRI标准化疗方案联合贝伐单抗治疗转移性结直肠癌疗效与不良反应分析[J].现代诊断与治疗,2017,28(21):3921-3924. 被引量：4
-
1郭广昌.企业家一定要相信点什么[J].IT时代周刊,2014,0(15):52-52.
-
2施歌.生命之悟[J].现代领导,2011(3):46-46.
-
3于春青.“手术”＋“化疗”，根除企业癌症[J].销售与市场,2011(20):36-37.
-
4陈聪,李炼,高瑞欣.宝洁公司概述[J].中国卫生监督杂志,1997,4(3):113-113.
-
5徐士谨.抓住员工的“痛点”[J].中外管理,2012(8):124-124.
-
6王路曼.空巢老人的“专职”司机[J].北京支部生活,2013(9):62-62.
-
7樊柯.聚焦企业家“精神病”[J].科学之友,2003(3):18-21.
-
8杜瑞文.儿子是父亲的铁撑腰[J].启迪与智慧（下）,2016,0(2):20-21.
-
9名利场[J].环球企业家,2014,0(14):16-17.
-
10语录[J].中国报道,2008(9):66-66.
